$dxcm 136.38
DexCom Raised to Market Perform From Underperform by Northland Securities
8:44 AM ET 9/12/18
$tndm 39.38
Shares of Tandem Diabetes Care Inc. are down about 15% to $40.28 in early afternoon trading, trimming some of the surge in the stock so far this year. On Friday, Robert W. Baird & Co. analyst Jeff Johnson lowered his rating on the stock of the San Diego-based insulin pump maker to neutral, writing in a research note that with shares recently priced at around 50 times Tandem's 2021 estimated Ebitda, "we believe valuation has to matter at some point, and as such we move to the sidelines" with the new rating. Despite Monday's losses, shares in the company are up about 1,600% so far this year on investor enthusiasm for Tandem's products for people with diabetes.
$trxc 6.45
Filed 510(k) submission for Senhance Ultrasonic, broadening the potential applicability of Senhance surgery in the U.S.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--September 06, 2018--
tr@nsEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company filed a FDA 510(k) submission for its Senhance Ultrasonic Instrument System.
Advanced energy devices, including ultrasonic devices, represent some of the most versatile and critical tools for surgeons in minimally invasive surgery. These instruments deliver controlled energy to effectively ligate and divide tissue, and minimize thermal injury to surrounding structures.
"Advanced energy devices are an important tool within laparoscopic surgery because of their applicability within a wide range of procedures, " said Todd M. Pope, tr@nsEnterix CEO. "Once approved, we believe the addition of the Senhance Ultrasonic will be a useful tool for surgeons and help drive broader penetration of Senhance and help advance digital laparoscopy in the U.S."
$lyv 53.01
UPDATE: Eventbrite IPO: 6 things to know about the ticketing company
By Emily Bary
Eventbrite says 95% of clients sign up for the service on their own
Despite its controversies, Ticketmaster-parent Live Nation Entertainment Inc. has been a winning stock over the past few years. The very things that make the company controversial -- high ticket fees and a stronghold on event venues -- have helped the company deliver impressive results quarter after quarter.
Soon, investors will have another public ticketing company to watch, though it operates quite a bit differently. Eventbrite Inc. has filed for an initial public offering and intends to test the market's appetite for a small-scale ticketing business that deals with lower-profile events and doesn't rely on exclusive access to major sporting events and the like.
Live Nation (LYV) has major promotional and venue-operations businesses, so it's not a perfect comparison to Eventbrite, which mainly deals with ticketing and event management. Eventbrite "doesn't fit into any bucket" but Live Nation "is the closest thing you can get publicly," said Phil Haslett, co-founder of EquityZen (↪🔗), an online marketplace for pre-IPO shares.
Both companies say they're benefiting from increased spending on experiences.
Eventbrite intends to go public on the New York Stock Exchange under the ticker EB. The company said Tuesday it plans to offer 10 million shares priced at $21 to $23 each, to raise $220 million at the midpoint of that range. The company was valued at more than $1 billion in a 2014 funding round, according to The Wall Street Journal